Hadassah Medical Organization
Jerusalem, 91120, Israel
NCT Number: NCT01962077
assess the effect of MedCem MTA as a pulp medicament following pulpotomy in human primary molars with carious pulp exposure in comparison to Formocresol.
Looking for future studies?
Notify Me2 year–10 year
All sexes
Interventional
Not applicable
Jerusalem, 91120, Israel
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Time frame: Up to 36 months
No pain, no swelling or sinus tract, no internal root resorption progressing into the bone, no furcation and/or periapical bond destruction.
Hadassah Medical Organization
Other
Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07541976
Dental Pulp Disease, Dental Pulp Diseases
Baghdad, Rusafa, Iraq
View Trial DetailsNCT07548008
Dental Caries, Pulpotomies Primary Teeth
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07168811
Dental Pulp Diseases, Pulp Disease, Dental
Cairo, Egypt
View Trial DetailsNCT07072559
Anxiety, Anxiety Disorders
Al Mansurah, Egypt
View Trial Details